Replies to post #29361 on Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

Don't forget ASCO abstract for '113...


8) Abstract #8031
First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.
D. R. Camidge, MD, PhD
Poster Board: #20